Issues
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Articles
Clinical Implications of Decreased Retinoblastoma Protein Expression in Acute Myelogenous Leukemia1
Comparative Antitumor Effects of Hormonal Ablation, Estrogen Agonist, Estrogen Cytotoxic Derivative, and Antiestrogen in the PAIII Rat Prostatic Adenocarcinoma
Cytogenetic Characterization of B-Cell Lymphomas from Severe Combined Immunodeficiency Disease Mice Given Injections of Lymphocytes from Epstein-Barr Virus-positive Donors1
Elevated DT-diaphorase Activity and Messenger RNA Content in Human Non-Small Cell Lung Carcinoma: Relationship to the Response of Lung Tumor Xenografts to Mitomycin C1
Resistance of Human Cervical Carcinoma Cells to Tumor Necrosis Factor Correlates with Their Increased Sensitivity to Cisplatin: Evidence of a Role for DNA Repair and Epidermal Growth Factor Receptor1
Characterization of a Complementary DNA for Rat Liver Aryl Sulfotransferase IV and Use in Evaluating the Hepatic Gene Transcript Levels of Rats at Various Stages of 2-Acetylaminofluorene-induced Hepatocarcinogenesis
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.